Innovation
Innovation powers the next generation of treatments and cures. See how PACH is working to protect and preserve cutting-edge medical innovation.
Inflation Reduction Act
Patients and policymakers hope to see lower health care costs from the Inflation Reduction Act, but there are unintended consequences, such as limited treatment options and stifled innovation, that may affect cardiovascular patients.
Genetically Targeted Technologies
Genetically targeted technologies use Nobel prize-winning science and can reduce patients’ number of pharmacy visits, simplify medication routines, and ultimately improve patients’ heart health management. But only if patients can access them.
Blogs
A MINI Act Could Be Big for Patients
Game-changing medical technology is on the line. Based on Nobel-prize winning science, genetically targeted technologies take on the proteins that cause disease. The medications are administered once or twice a year to treat rare and debilitating diseases, from Duchenne muscular dystrophy to high cholesterol.
What Price Negotiation Could Mean for New Heart Medications
Lower out-of-pocket prescription drugs costs spread more manageably across the calendar year. That’s what patients and policymakers alike hope to get from the Inflation Reduction Act.
Graphics
Genetically Targeted Technologies: Targeted Treatment
Social media graphic
Genetically Targeted Technologies: Congress Can Help
Social media graphic
Genetically Targeted Technologies: Nobel Prize-Winning Science
Social media graphic
The MINI Act: A Big Win for Heart Patients
Innovation promises new ways to deliver medication. One example is genetically targeted technologies.
Papers
Genetically Targeted Technologies and the MINI Act
Genetically targeted technologies have many benefits for heart patients and the MINI Act can help patients have access to these treatments by encouraging ongoing medical innovations.
Overview and Outlook for RNA-Based Therapies
Avalere study
Post-Approval Indications and Clinical Trials for Cardiovascular Drugs: Some Implications of the U.S. Inflation Reduction Act
To describe the historical baseline landscape of cardiovascular drug post-approval activity, including the number and timing of post-approval clinical trials and approved indications. The US Inflation Reduction Act of 2022 (IRA) Drug Price Negotiation Program (DPNP) and its Maximum Fair Prices (MFPs) will affect incentives for investment in post-approval activity such as clinical trials for […]
Videos
A MINI Act Could Be Big for Heart Patients
The MINI Act would allow more time for research, investment and infrastructure in the development of novel therapies like genetically targeted technologies for heart patients.
[Webinar] Will Patients Benefit from IRA's Maximum Fair Price?
Listen to Robert Popovian, PharmD, Anne Sydor, PhD, and Ryan Gough as they discuss the impact of the Inflation Reduction Act's maximum fair price on patients.
[Webinar] Genetically Targeted Technologies and the MINI Act
Listen to Michael Gibson, MS, MD, Chris Kelly and Ryan Gough as they discuss the need for ongoing innovation and how policy can encourage breakthrough treatments like genetically targeted technologies.
Understanding Genetically Targeted Technologies
Innovation promises new ways to deliver medication. One example is genetically targeted technologies.